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Multippeliskleroosi eli MS-tauti on Suomessa nuorten aikuisten yleisin invalidisoiva 
keskushermoston sairaus ja yleisin demyelinaatiosairaus. Tässä tutkimuksessa selvitettiin 
MS-tapausten ilmaantuvuutta Tampereen Yliopistollisessa sairaalassa vuosina 2010-2014 ja 
ennustekijöitä taudin etenemiselle. Aineisto koostui 202 varmistetusta MS-potilaasta ja 
tutkimusta koskevat tiedot kerättiin retrospektiivisesti potilasasiakirjoista. Naisten ja 
miesten suhde oli 2.7 ja ikävakioitu insidenssi 10.3 CI 95%: 8.8-11.7).  
 
 
Insidenssikohortin Coxin regressioanalyysissä primaarisprogressiivinen taudinkulku (PPMS) 
(p=0,040), multippelit (p=0,011), motoriset (p=0,000), sensoriset (p=0,037) sekä visuaaliset 
(p=0,008) ensioireet, pitkittynyt viive diagnoosiin (p=0,000) sekä potilaan korkea ikä 
diagnoosihetkellä (p=0,005) ennustivat edenneempää tautia. Erillisessä relapsoivaa-
remittoivaa taudinkulkua (RRMS) sairastavien potilaiden analyysissä multippelit (p=0,013) ja 
motoriset (p=0,005) ensioireet, aktiivinen tupakointi (p=0,047), pitkittynyt viive diagnoosiin 
(p=0,000) sekä potilaan korkea ikä diagnoosihetkellä (p=0,003) ennustivat edenneempää 
tautia. Ne tupakoitsijat, joilla oli lisäksi muita samanaikaisia sairauksia (depressio ja/tai 
diabetes) olivat suurentuneessa riskissä saavuttaa EDSS 2.5 seurannan loppuun mennessä ja 
multivariaabelissa Coxin regressioanalyysissä aktiivisten tupakoitsijoiden riski saavuttaa EDSS 
2.5 oli yli kaksinkertainen verrattuna tupakoimattomiin. Kun aggressiiviset RRMS-tapaukset 
suljettiin pois Kaplan-Meyerin analyysista, havaittiin, että RRMS-potilaat, joilla oli käytössä 
taudinkulkua muokkaava lääkitys, saavuttivat seurannan loppuun mennessä EDSS 2.5 –tason 
myöhemmin kuin ne, joilla ei ollut lääkitystä (log rank p=0,006). Tutkimuksessa havaittiin, 
että toimintakyvyn heikentymistä voidaan havaita jo lyhyessä seurannassa, mutta yhä 
tarvitaan kuitenkin pidemmän seuranta-ajan tutkimuksia, jotta voitaisiin tutkia myös 
pitkäaikaisennusteeseen vaikuttavia tekijöitä.  
 
 
Tämän opinnäytteen alkuperäisuus on tarkastettu Turnitin OriginalityCheck -ohjelmalla 
Tampereen yliopiston laatujärjestelmän mukaisesti.  
 
 
 
  
1 VOCABULARY  
 
 
 
AMS Aggressive multiple sclerosis 
ASC Adult stem cells 
BBB Blood-brain barrier 
BMS Benign multiple sclerosis 
CIS  Clinically isolated syndrome 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DIS Dissemination in space 
DIT Dissemination in time 
DMT Disease modifying treatment 
EDSS Extended disability status scale 
EP Evoked potential 
HSC Hematopoietic stem cells 
IFN Interferon 
IgG Immunoglobulin G 
KM Kaplan-Meyer 
MBP Myelin basic protein 
MRI Magnetic resonance imaging 
MSC  Mesenchymal stem cells 
MxA Myxovirus resistance protein A 
NEDA  No evidence of disease activity’ 
NSC Neural stem cells 
PPMS Primary progressive multiple sclerosis 
S1P  Sphingosine 1-phosphate  
SPMS Secondary progressive multiple sclerosis 
STC Stem cell therapy 
RCT Randomized controlled trial 
RIS Radiologically isolated syndrome 
RRMS Relapsing-remitting multiple sclerosis 
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2 INTRODUCTION 
 
 
 
Multiple sclerosis is a chronic inflammatory and neurodegenerative autoimmune disease of 
the brain and spinal cord. In Finland MS is the most common disease of the central nervous 
system (CNS) among young adults and also the most common demyelinating disease (Tienari 
2016). Approximately 2.5 million people globally and more than 7000 people in Finland are 
affected by MS (Dendrou et al. 2015, Tienari 2016). The average age of disease onset is 
approximately 30 years (Dendrou et al. 2015).  
 
 
Prognosis is highly individual, but approximately 50% of patients have reached a permanent 
disability after 25 years from diagnosis (Dendrou et al. 2015). The course of multiple 
sclerosis can be divided into two main types: Relapsing-remitting multiple sclerosis (RRMS) 
and primary progressive multiple sclerosis (PPMS) (Lublin et al. 2014). In a previous Finnish 
study, 89% of patients the disease began as RRMS, characterized by recurring relapses and 
remission phases, but about 11% of patients were affected by PPMS, which leads to more 
steady disability accumulation (Sumelahti et al. 2014). Like said, the degree of progression in 
MS varies, but approximately after seven years from RRMS initiation a secondary phase 
begins and disease reaches the secondary progressive (SPMS) phase, characterized by 
accumulating disability and paucity of exacerbations (Grigoriadis and van Pesch 2015).  
 
 
Comorbidity denotes the presence of additional diseases co-occurring with MS. Comorbidity 
in MS has been linked to increased delay of diagnosis, more frequent hospitalizations, lower 
quality of life, faster progression of the disease and higher mortality (Capkun et al 2015, 
Marrie et al. 2009, 2015a, b). Most common comorbidities include depression, anxiety, 
hypertension, hyperlipidemia and chronic lung disease (Marrie et al. 2015c). Smoking and 
obesity in childhood and adolescence have been proven to be risk factors for MS 
(Gianfrancesco et al. 2014, Hawkes 2007, Hedström et al. 2013, Hernan et al. 2005, Langer-
Gould et al. 2013, Munger et al. 2013, Ramanujam et al. 2015, Riise et al. 2003).  
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The first line disease-modifying treatments (DMT) developed for MS are effective mainly in 
the RRMS (Palmer 2013). Treatment aims at reduction of symptoms and disability accrual, 
which lead to better quality of life and today also prevention of the disease progression 
(Palmer 2013). Current first line choises of medication include older injectables,such as 
interferon beta (IFN-β) and glatiramer acetate and newer peroral medications, dimethyl 
fumarate and teriflunomide (Multiple sclerosis: Current care guidelines 2015). Other 
treatment choices include peroral fingolimod and infusion treatments, such as 
mitoxantrone, alemtuzumab, natalizumab and daclizumab (Multiple sclerosis: Current care 
guidelines 2015). Treatment option in PPMS  is ocrelizumab, which was recently approved 
for both RRMS and PPMS by the U.S. Food and Drug Administration (FDA) (Hauser et al. 
2015, Montalban et al. 2015). 
 
 
 
3 EPIDEMIOLOGY 
 
 
 
Multiple sclerosis is distributed geographically unevenly and predominantly affects northern 
Europeans (Sumelahti et al. 2001). The prevalence of multiple sclerosis is highest in 
Scandinavia and is higher than average for example in North-America, United Kingdom and 
Ireland populated by the ancestors of the scandinavians (Simpson et al. 2011). The MS 
prevalence is globally around 120/105 personyears and incidence around 7/105 personyears 
(Compston and Coles 2002).  
 
 
Finland is a high risk district and prevalence is about 130/105 personyears and yearly 
incidence about 7/105 personyears (Multiple sclerosis: Current care guidelines 2015). MS is 
more common in the western than in the southern Finland, even if the Finnish population is 
regarded genetically homogenous (Sumelahti et al. 2001, 2014). Prevalence as high as 200-
300/105 has been reported in the south-western area of Seinäjoki (Sumelahti et al. 2001). 
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This is at least in part caused by familial clustering (Sumelahti et al. 2001). At the same time 
the rapidly increased incidence indicates action of yet unidentified environmental factors 
(Sumelahti et al. 2001).  
 
 
MS incidence is influenced by genes and environmental factors, such as latitude, sex and 
ethnicity (Pugliatti et al. 2006). According to Danish multiple sclerosis registry studies MS 
incidence decreased through the 1950s, then increased among the male population and 
since 1970s increased substantially among the female population (Koch-Henriksen et al. 
2011). At the same time the female to male ratio has increased from 1950 to 1999 from 
1.3:1 to 2.2:1 (Koch-Henriksen et al. 2011). The increased prevalence is due to rising 
incidence, but also due to better survival of MS patients seen in the markedly increased 
number of old MS patients (Koch-Henriksen et al. 1999).  
 
 
 
4 CAUSES OF MULTIPLE SCLEROSIS 
 
 
 
The exact cause of MS remains unknown, but several environmental as well as genetic 
factors have been identified as aetiologic factors of MS.  
 
 
It seems that multiple sclerosis manifests in genetically susceptible patients under the 
influence of environmental factors (Compston and Coles 2002). The concordance of 
monozygotic twins was 24% in the Danish studies and for dizygotic twins it was 3%, like for 
any other siblings (Koch-Henriksen et al. 2011). The risk is 7-10 times higher in the children 
and siblings of a multiple sclerosis patient (Koch-Henriksen et al. 2011). Epigenetic and post-
genomic events have effect in the development of MS (Grigoriadis and van Pesch 2015). 
Multiple sclerosis seems to be polygenic and multiple polymorphisms contribute to disease 
development and thus about 30% of the disease risk can be explained with genetic factors 
(Dendrou et al. 2015). The strongest susceptibility gene is HLA-DRB1*15, which elevates the 
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odds ratio for homozygotes to 7.0 and for heterozygotes to 3.5-5.0 (Pugliatti et al. 2006). 
Other genes in the human leukocyte antigen gene cluster, such as HLA-A and HLA-B and over 
100 non-HLA-regions have been linked to multiple sclerosis susceptibility, but have milder 
effect on the susceptibility of MS (Pugliatti et al. 2006). Odds ratios for the non-HLA-genes 
range between 1.09-1.34 (Pugliatti et al. 2006). These genomic regions overlap considerably 
with other autoimmune diseases, but little with other neurodegenerative diseases, which 
reinforces the autoimmune theory of MS (Dendrou et al. 2015).  
 
 
Environmental factors have been studied extensively, but no single prominent factor has yet 
been discovered. Low exposure to ultraviolet radiation and vitamin D deficiency, smoking, 
shift work, obesity and Epstein-Barr virus infection and upper respiratory infections have 
been associated with increased risk of MS. Physical trauma, emotional stress or vaccinations 
have not been linked to risk for multiple sclerosis. (Grigoriadis and van Pesch 2015, Mowry 
2011) 
 
 
Smoking is one of the strongest risk factors for MS (Hawkes 2007, Hedström et al. 2013, 
Hernan et al. 2005, Riise et al. 2003). Cumulative dose, duration and intensity of smoking 
influence the risk regardles of age at smoking debut (Riise et al. 2003). The risk is reduced to 
the level of non-smokers in a decade after cessation of smoking (Riise et al. 2003). Smoking 
also accelerates disease progression (Healy et al. 2009). In a cross-sectional survey and 
longitudinal follow-up by Healy et al. (2009) 1465 patients with clinically definite MS were 
followed approximately three years. It was found that smokers’ disease was significantly 
more severe, they progressed faster and their T2-weighted lesion volume increased and 
brain parenchymal fraction decreased faster than those of never-smokers. 
 
 
Furthermore, the intestinal microbiome and diet with high fat and salt content may alter the 
immune responses and contribute to the development of MS (Grigoriadis and van Pesch 
2015). Obesity is a chronic, inflammatory state (Aguilar-Valles et al. 2015). It seems that the 
proinflammatory adipokines produced by adipose tissue become dominant in obesity and 
this imbalance functons as a link between obesity and autoimmune diseases, such as 
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multiple sclerosis (Aguilar-Valles et al. 2015). The association between obesity in childhood 
and adolescence and increased risk of MS in females has been established (Gianfrancesco et 
al. 2014, Langer-Gould et al. 2013, Munger et al. 2013). 
 
 
 
5 PATHOGENESIS  
 
 
 
5.1 Immunology of relapsing-remitting multiple sclerosis 
 
 
Immune cell infiltration and focal inflammation is more prominent in RRMS and early in the 
disease (Grigoriadis and van Pesch 2015). Immune dysregulation involves both innate and 
adaptive immune systems (Grigoriadis and van Pesch 2015). According to the predominate 
theory demyelination is caused mainly by autoreactive T- and B-lymphocytes which initiate 
abnormal responses against autoantigens of the myelin sheath, but also by aberrant 
function of regulatory cells (Dendrou et al. 2015, Grigoriadis and van Pesch 2015). Microbes 
and viruses can activate T cells, B cells and monocytes through molecular mimicry 
(Compston and Coles 2002, Dendrou et al. 2015).  
 
 
Dendritic cells become activated after recognizing an antigen and present the antigen to the 
CD4+ T cells and CD8+ T cells (Elovaara and Soilu-Hänninen 2006, Grigoriadis and van Pesch 
2015). T cells express adhesion molecules and penetrate the blood brain barrier (BBB) at the 
choroid plexus (Compston and Coles 2002, Dendrou et al. 2015, Grigoriadis and van Pesch 
2015). After infiltrating to the CNS they are reactivated by microglia and dendritic cells 
resulting in differentation to IFN-γ secreting Th1 and IL-17 secreting Th17 cells (Dendrou et 
al. 2015). Th17 cells also produce matrix metalloproteinase and reactive oxygen species 
which increase the permeability of BBB (Grigoriadis and van Pesch 2015). T cells release 
inflammatory mediators which cause breakdown of BBB and injury of axons and glia causing 
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loss of myelin sheath and oligodendrocytes (Compston and Coles 2002, Dendrou et al. 2015). 
Number of CD8+ T cells correlates with the extent of axonal damage (Dendrou et al. 2015).  
 
 
Activated microglia produce pro-inflammatory cytokines and chemokines, which attract 
macrophages from the periphery (Elovaara and Soilu-Hänninen 2006). They produce toxic 
inflammatory mediators and reactive oxygen and nitroges species resulting in oxidative 
injury of axons and mitochondrial dysfunction (Grigoriadis and van Pesch 2015). This causes 
demyelination and axonal loss (Grigoriadis and van Pesch 2015). Microglia and macrophages 
remain activated throughout the disease (Dendrou et al. 2015). 
 
 
Microglia and astrocytes produce neurotrophic growth factors and microglia also clear cell 
debris, which makes them essential for remyelination, but over time this leads to gliosis 
creating a physical barrier to remyelination (Compston and Coles 2002). This results in brain 
atrophy, which is related to permanent disability accumulation (Compston and Coles 2002). 
Astrocytes control infiltration of leukocytes to the CNS and regulate the activity of microglia, 
oligodendrocytes and adaptive immune cells (Grigoriadis and van Pesch 2015).  
Antigens also activate the B cells which penetrate the CNS and produce antibodies 
intrathecally (Elovaara and Soilu-Hänninen 2006, Grigoriadis and van Pesch 2015). 
Immunoglobulin G (IgG) antibodies activate the complement resulting in membrane attack 
complex formation and demyelination (Elovaara and Soilu-Hänninen 2006).  
 
 
Decreased amount and abnormal function of regulatory T cells may cause the appearance of 
the autoreactive T and B cells. These cell types may also be resistant to suppressive actions 
of regulatory T-cells. (Dendrou et al. 2015) 
 
 
5.2 Immunology of progressive multiple sclerosis 
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In PPMS there are less inflammatory lesions, which are also smaller (Confavreux and Vukusic 
2006). Cortical demyelination and diffuse axonal injury throuhgout the normal-appearing 
white matter are more pronounced in progressive forms of MS (Grigoriadis and van Pesch 
2015). Axonal loss is most prominent in the secondary progressive phase. (Compston and 
Coles 2002) Degeneration is characterized by axonal loss, gliosis and astrocyte proliferation 
(Elovaara and Soilu-Hänninen 2006).  
 
 
Progression is caused by axonal damage triggered by inflammation but it seems to proceed 
independent of that. Progression may start early, even before the first clinical signs of 
multiple sclerosis. (Compston and Coles 2002) 
 
 
The number of B cells increases with age in primary or secondary progressive diseases 
(Dendrou et al. 2015). CNS infiltrating lymphocytes may cause the formation of tertiary 
lymphoid structures into the meninges of patients with progressive disease form (Elovaara 
and Soilu-Hänninen 2006). These formations may be responsible of maintaining the B cell 
responses in the CNS, but their significange in MS pathogenesis is still unclear (Elovaara and 
Soilu-Hänninen 2006). Microglia are activated throughout the normal appearing white 
matter and in the inflammatory plaques (Elovaara and Soilu-Hänninen 2006). They produce 
reactive oxygen and nitrogen species which cause demyelination of the normal appearing 
white matter, but also in the gray matter resulting in neuroaxonal damage and brain atrophy 
(Elovaara and Soilu-Hänninen 2006).  
 
 
5.3 Signs of blood brain barrier damage 
 
 
Blood brain barrier (BBB) damage in MS pathogenesis is observed in cerebrospinal fluid (CSF) 
finding typical of BBB damage is increased protein level and in the case of MS increased 
intrathecal IgG synthesis which can be seen in electrophoresis as oligoclonal bands and as 
elevated IgG index. The IgG index is the ratio of CSF IgG to CSF albumin to the ratio of serum 
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IgG to serum albumin. IgG index of over 0.7 indicates intrathecal IgG synthesis.  (Rammohan 
2009) 
 
 
BBB breaching can be observed with magnetic resonance imaging (MRI) as gadolinium-
enhancing lesions indicating acute inflammation (Mowry 2011). Lesions have a predilection 
for the periventricular, juxtacortical, infratentorial and brain stem white matter and 
depending on the cite of the lesion, demyelination can cause variable symptoms that cause a 
clinical exarberation called bout (Multiple sclerosis: Current care guidelines 2015).  
 
 
 
6 DIAGNOSIS 
 
 
 
6.1 Basis of the diagnosis 
 
 
Currently MS is diagnosed using the McDonald criteria 2010. The diagnosis is a clinical 
outcome of clinical and paraclinical tests. Paraclinical tests used in the diagnosis of MS are 
MRI, evoked potentials (EP) and CSF studies including protein content, IgG index and 
electrophoresis. (Multiple sclerosis: Current care guidelines 2015) 
 
 
6.2 Diagnosis of RRMS 
 
 
Diagnosis of RRMS requires exclusion of other possible causes of symptoms and evidence of 
dissemination in time (DIT) and space (DIS). Therefore McDonald criteria 2010 are fulfilled 
when patient has suffered from at least two clinical relapses and lesions of at least two 
functional systems are present. In this case no additional tests are needed.  
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If patient has had at least two clinical relapses, but has only one objective clinical CNS lesion, 
dissemination in space needs to be shown with MRI or as a new relapse caused by lesions of 
another functional system. MRI dissemination in space requires at least two T2 lesions in at 
least two of the following cites of CNS: Periventricular, juxtacortical or infratentorial white 
matter or medulla. (Multiple sclerosis: Current care guidelines 2015) 
 
 
If a patient has has only one clinical relapse, but has at least two clinical CNS lesions, 
dissemination in time needs to be demostrated by additional clinical relapse or by MRI. MRI 
dissemination in time requires gadolinium-enhancing and non-enhancing lesions in a single 
MRI or at least one new T2 or Gd-enhancing lesion in a single MRI. If patient has had only 
one clinical relapse and one CNS lesion (CIS patient), dissemination in space and time needs 
to be shown in a previously described manner. (Multiple sclerosis: Current care guidelines 
2015) 
 
 
6.3 Diagnosis of PPMS 
 
 
PPMS can be diagnosed when patient has had at least one year of steady progression and at 
least two of the following criteria are fulfilled:  
1. Dissemination in space based on one or more T2 lesions in regions characteristic of 
MS (periventricular, juxtacortical or infratentorial white matter) 
2. Dissemination in space based on at least two T2 lesions of  brain stem 
3. Positive CSF studies (oligoclonal bands, isoelectric focusing or elevated IgG index) 
(Multiple sclerosis: Current care guidelines 2015) 
 
 
7 DISEASE COURSE 
 
7.1 Disease course in Finnish MS population 
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In a previous Finnish study 89% of patients were affected by RRMS and 11% by PPMS 
(Sumelahti et al. 2014). Multiple sclerosis can be considered as a single disease with 
different patterns of evolution (Confavreux and Vukusic 2006). Relapsing-remitting course of 
the disease can be regarded as pre-progression phase before converting to secondary 
progressive disease (SPMS) (Confavreux and Vukusic 2006). PPMS and SPMS have similar 
onset age and initial symptoms at onset of progressive phase, but accumulation of disability 
is faster and occurs earlier in primary progressive MS (Confavreux and Vukusic 2006). RRMS 
is more common in women (female/male ratio 2.2 for RRMS and 1.3 for PPMS) and begins 
earlier than PPMS (Sumelahti et al. 2014). For example in a Finnish 30-year follow-up study 
the mean age at diagnosis was 36.3 in RRMS group and 45.3 years in PPMS group (Sumelahti 
et al. 2014).  
 
 
7.1 CIS 
 
 
RRMS is initially presented as the first neurological symptom, referred to as clinically isolated 
syndrome (CIS) after an asymptomatic period of unknown duration (Kantarchi and 
Weischenker 2006). CIS is followed by a remission period, but not all patients develop any 
other symptoms (Kantarchi and Weischenker 2006). Usually relapses occur with highly 
variable rate, median interval between relapses being approximately one year (Compston 
and Coles 2002).  
 
 
Disease-modifying therapy can reduce the risk of developing second demyelinating event, 
which makes it interesting to search for early prognostic factors of disease progression from 
CIS to relapsing-remitting phase (Mowry 2011). It has been established that non-white race, 
younger age and lower number of functional systems involved are associated with higher 
risk for second attack (Mowry 2009).  
 
 
7.2 RRMS 
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Relapsing-remitting phase is characterized by relapses of acute neurological symptoms 
ending up with partial or complete remission. Relapses are mainly caused by acute 
inflammation. Symptoms can be new or previous symptoms can worsen. (Confavreux and 
Vukusic 2006) 
 
 
Bout is a new or abruptly worsened neurological symptom lasting at least 24 hours and at 
most 4 weeks. A bout should be separated from worsening of previous symptoms due to 
temperature or infection. Bouts are treated with high dose i.v. steroids, which shortens the 
duration of symptoms but does not seem to have effect on the long-term prognosis. 
(Multiple sclerosis: Current care guidelines 2015) 
 
 
Symptoms include for example muscle weakness, spasticity, sensory symptoms, optic 
neuritis, diplopia and cerebellar disturbance including dysarthria, ataxia and tremor. Slowed 
cognition, impaired memory and depression are common especially in progressive MS. 
Affected neurons conduct impulses slower and may show mechanical (Lhermitte's symptom) 
and heat sensitivity (Uhthoff's phenomenon). Demyelinated axons may "cross-talk" causing 
paroxysmal symptoms, such as trigeminal neuralgia or ataxia. (Compston and Coles 2002)  
 
 
Plaques can be partially repaired by remyelination at least early in the disease resulting in 
multifocal sclerotic lesions (Dendou et al. 2015). Remyelination, sodium channel formation 
and neuronal plasticity compensate the damage causing the acute symptoms to resolve and 
appear again (Ruutiainen et al. 2006). Accompanying axonal injury causes disability 
accumulation (Kantarchi and Weinshenker 2005). Approximately 75% of RRMS patients 
convert to SPMS in 25 years from disease onset (Confavreux and Vukusic 2006). Conversion 
to secondary progression is believed to occur when threshold of axonal damage is crossed 
and the neuronal plasticity can no longer compensate (Confavreux and Vukusic 2006). 
Secondary progressive MS is characterized by CNS atrophy and progressive disability 
accumulation (Dendou et al. 2015).   
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7.3 PPMS 
 
 
PPMS is characterized by absence of relapses and paucity of radiological evidence of acute 
inflammation from onset. Progressive course is itself a predictor of poor outcome, but also 
involvement of at least three functional systems in PPMS serves as a predictor of worse 
outcome. The delay in seeking medical care is often longer in patients with PPMS than in 
patients with RRMS due to lack of clear exacerbations. (Confavreux and Vukusic 2006) 
 
 
7.5 RIS 
 
 
Incidental MRI findings consistent with multiple sclerosis that are not associated with any 
clinical symptoms of MS are referred to as radiologically isolated syndrome (RIS) and not 
concidered as a form of multiple sclerosis since it lacks sufficient evidence of excistence of 
multiple sclerosis. About 30% of RIS patients have an exaberbation in 5 years. (Multiple 
sclerosis: Current care guidelines 2015) 
 
 
 
8 CLASSIFICATION OF DISEASE ACTIVITY 
 
 
 
8.1 Active and non-active MS 
 
 
All types of MS (RRMS, PPMS and CIS) can be further categorized in active and non-active 
depending on the manifestations of clinical relapses presence of new T2- or gadolinium-
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enhancing lesions over a certain period of time in RRMS , or progression of disability in both 
RRMS and PPMS (Grigoriadis and van Pesch 2015). In addition to disease course, 
classification in active and non-active forms is important in selecting patients to disease 
modifying therapies.  
 
 
8.2 Aggressive and benign MS 
 
 
The course of multiple sclerosis varies dramatically between individuals. Others develop only 
minimal disability over the course of the disease but others suffer from aggressive disease 
with rapid disability accumulation and repeated severe attacks. (Rush et al. 2015) 
 
 
Multiple sclerosis is considered benign if the disease is minimally progressive and does not 
cause substancial disability accumulation (Confavreux and Vukusic 2006, Correale et al. 
2012). Symptoms of benign multiple sclerosis are mainly motor (Correale et al. 2012). The 
criteria for benign multiple sclerosis (BMS) are still controversial, but EDSS (Extended 
Disability Status Scale) below 3 after 10 years from disease onset is widely used as a criterion 
for BMS (Correale et al. 2012). It seems that BMS patients principally suffer from cognitive 
disability, fatigue, pain and depression (Correale et al. 2012). It has been found that male 
gender, lower number of relapses in the first 5 years and baseline cognitive impairment and 
T1 lesion burden are risk factors for BMS (Correale et al. 2012). BMS incidence has been 
ranging between 5 and 64 % depending on the criteria used but for example in a Correale et 
al. (2012) study the incidence was 12.5%. 
 
 
The terms of aggressive and malignant MS have been ambiguous, but there has been 
increasing interest in defining the aggressive multiple sclerosis. The term of malignant 
disease should be reserved to fulminant multiple sclerosis, such as the Marburg variant that 
results in death within months or few years (Menon et al. 2013, Rush et al. 2015).  
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Menon et al. (2013) have categorized aggressive multiple sclerosis (AMS) into three groups. 
AMS1-group reached EDSS 6 within 5 years from onset symptom, AMS2-group reached EDSS 
6 by age 40 and AMS3-group converted to SPMS within 3 years from RRMS onset. The 
researchers constituted a combined population of the patients that did and did not 
(comparator cohort) fulfill the criterion for each AMS group. 5.5% of the combined AMS1-
group were categorized as AMS1, 14.0% of the combined AMS2-group were categorized as 
AMS2 and 4.0% of the combined AMS3-group were categorized as AMS3. In both AMS1 and 
AMS2 groups the AMS patients were more likely to be male and have primary progressive 
disease course compared to control cohort. AMS1 patients were more likely to be older and 
AMS2 patients younger than the controls at the time of MS onset. AMS3 patients were more 
likely to be male and older at MS onset than the controls. Therefore, depending on the 
definition used in approximately 4-14% of patients the disease course could be defined as 
aggressive. (Menon et al. 2013) 
 
 
According to Rush et al. (2015) aggressive multiple sclerosis can be defined as any type of 
MS that is rapidly progressive. RRMS can be defined aggressive when EDSS score reaches 4 
within 4 years from onset, annual relapse rate exceeds two relapses per year and resolution 
from those is imperfect, follow-up MRI shows more than two new or enlarging T2-lesions or 
gadolinium-enhancing lesions despite treatment or the patient does not respond to 
treatment with one or more DMT in a year. Male sex, disease onset at older age, cognitive, 
motor, cerebellar and/or spinchter impairment, especially if multifocal, more severe 
exacerbations and poor recovery indicate more severe disease course. High lesion load, 
infratentorial lesions or atrophy at first MRI and presence of new T2 or Gd-enhancing lesions 
at follow-up MRI may also help to identify aggressive MS. (Rush et al. 2015) 
 
 
In a study of Kaunzer et al. (2016) the criteria for AMS were  
1) two or more relapses in a year after MS onset and two or more Gd-enhancing 
lesions on brain MRI  
2) one relapse if it results in sustained baseline EDSS score of 3 and two or more Gd-
enhancing lesions on brain MRI. 
In this study 7.4 % of all MS patients had aggressive multiple sclerosis. (Kaunzer et al. 2016) 
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According to another classification by Gholipour et al. (2011) malignant (or aggressive) MS 
could be described as disease with rapid disability accrual of EDSS 6 in 5 years after disease 
onset. In this study the incidence of malignant MS was 12.11%. Malignant disease could be 
divided to transient and sustained malignant MS. Older, male patients and smokers were 
more likely to develop sustained malignant MS. (Gholipour et al. 2011) 
 
 
 
9 MORTALITY AND FACTORS AFFECTING PROGNOSIS AND SURVIVAL IN MS 
 
 
 
Multiple sclerosis is associated with a higher risk of death compared to general population 
(Multiple sclerosis: Current care guidelines 2015). In over half of the MS patients the death is 
caused from complications of multiple sclerosis (Phadke 1987, Bronnum-Hansen et al. 2004). 
Multiple sclerosis shortens life expectancy approximately 10 years, but in patients with 
onset occurring over the age of 50 the life expectancy is even shorter (Phadke 1987, 
Bronnum-Hansen et al. 2004). In Finland the mortality rate is 2.2-fold in male and 3.4-fold in 
women with multiple sclerosis than in age-matched controls (Sumelahti et al. 2010). 
 
 
The beneficial survival is associated with visual or sensory initial symptoms, while motor, 
cerebellar or spinchter symptoms and initially progressive course, male gender, older age 
and multifocal symptoms at onset relate to worse outcome (Eriksson et al. 2003, Gholipour 
2011, Kantarchi and Weinshenker 2005).  
 
 
Smoking after the diagnosis of MS is associated with acceleration of disease progression and 
cessation of smoking decelerates the progression (Hedström et al. 2013, Ramanujam 2015, 
Zivadinov et al. 2009). MRI-scans of the smokers show increased number of contrast-
 
16
enhancing lesions, increased T1 and T2 lesion volumes and brain atrophy (Zivadinov et al. 
2009). 
 
 
Studies have found that the incidence of infections, cardiovascular diseases, other systemic 
diseases and psychiatric disorders is higher and incidence of cancer lower in the MS 
population (Chapkun et al. 2015). In a large population-based study comorbidities were 
associated with increased mortality but the MS population had less total comorbidity than 
the matched population (Marrie et al. 2015). Higher mortality was observed only for 
depression compared to matched controls (Marrie et al. 2015). 
 
 
Usually the future course of the disease can be predicted quite reliably from the first 5 years 
in the disease (Confavreux and Vukusic 2006). Recognition of early predictive factors of 
conversion of CIS to clinically definite MS and RRMS conversion to SPMS is important in 
selection of patients to disease modifying therapies (Eriksson et al. 2003).  
 
 
PPMS is associated with worse prognosis and more rapid disability accrual (Kantarchi and 
Weinshenker 2005, Levic 1999). In RRMS high relapse frequency predicts worse outcome 
and conversion to secondary progression (Kantarchi and Weinshenker 2005). In relapsing-
remitting MS incomplete recovery from relapses and secondary progression together 
accumulate fixed disability (Compston and Coles 2002). If the first MRI shows signs of MS in 
a CIS patient, the risk of developing multiple sclerosis is 88% and if not, the risk is 19% (Brex 
et al. 2002). Increasing MRI lesion load indicates higher risk of developing MS (Confavreux et 
al. 2000).  
 
 
Conversion to secondary progression and time to reach EDSS 6 can be predicted from 
greater number of functional systems involved, high relapse rate, poor remission from early 
exacerbations and short time to early disability (Eriksson et al. 2003). Patients who reached 
EDSS 3 faster had a shorter interval between EDSS 3 and EDSS 6 (Eriksson et al. 2003). Early 
cognitive symptoms also imply higher risk of secondary progression (Eriksson et al. 2003). 
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None of the early predictors could predict rate of secondary progression indicating that 
pathogenesis of secondary progression is separate from pathogenesis of early relapsing-
remitting phase (Confavreux and Vukusic 2006, Confavreux et al. 2000, Eriksson et al. 2003).  
 
 
Pregnancy seems to affect the relapse rate. During the pregnancy, relapse rate is at its 
lowest in the third trimester and rises instantly after parturition. After 3 months the relapse 
rate lowered to the pre-pregnancy level. (Kantarchi and Weinschenker 2005).  
 
 
 
10 TREATMENT 
 
 
 
10.1 Effect of disease modifying treatment 
 
 
Prior to current disease modifying therapies multiple sclerosis was handled with 
immunosuppressive drugs, such as cyclophosphamide. They were problematic not only 
because of their toxicity but also for their modest efficacy. (Rush et al. 2015) 
 
 
Treatments are not specific enough and therefore they often have side-effects including flu-
like symptoms, opportunistic infections and other autoimmune and malignant diseases. 
Injectable treatments often cause adverse skin reactions, such as erythema, itching, edema 
and occasionally lipoatrophy (Dendrou et al. 2015, Elovaara and Soilu-Hänninen 2006). 
These side-effexts can weaken log-term adherence to therapy (Confavreux and Vukusic 
2006).   
 
 
Current immunological therapies are targeted mainly against infiltration of CNS by immune 
cells seen most prominently in relapsing-remitting course of the disease (Kantarchi and 
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Weinshenker 2005). DMT:s cause reduction of relapse frequency, attack severity and 
radiological evidence of inflammation (Kantarchi and Weinshenker 2005). Early intervention 
may prevent disability accumulation caused by axonal loss, but this has not been established 
yet due to the long time needed for disability accumulation (Confavreux and Vukusic 2006). 
Therefore DMT:s are currently used in RRMS patients who show continuing active 
inflammation.  
 
 
According to current knowledge multiple sclerosis begins with an asymptomatic phase of 
variable duration. Even the first MRI often shows dissemination in time and/or space proving 
that the disease has already been proceeding before the initial symptoms. (Elovaara and 
Soilu-Hänninen 2006) 
 
 
MRI can be used in evaluation of treatment effectiveness, especially in the first years from 
treatment onset. New or expanding gadolinium-enhancing or T2-weighted lesions signal 
disease activity and are a subject for concideration of treatment enhancement.  Patient who 
suffers from disease activity during use of first line medication is often switched to secind 
line medication, such as natalizumab. (Multiple sclerosis: Current care guidelines 2015) 
 
 
10.2 Current treatment practice in Finland 
 
 
The Social Insurance Institution of Finland requires at least two confirmed episodes of 
neurological dysfunction or one episode and temporally distinct MRI finding of 
demyelination to grant reimbursements for first-line treatments 
(http://www.kela.fi/laake303 8.7.2016). Fingolimod (Gilenya®) is reimbursable if the 
relapsing-remitting MS is very active despite of at least one DMT. Thus the time interval 
from disease onset to the beginning of disease modifying treatment is lengthy and allows 
disease development in the early phase (Elovaara and Soilu-Hänninen 2006). On the other 
hand not every patient needs DMT and it may cause yet unidentified adverse effects in the 
long run (Elovaara and Soilu-Hänninen 2006). 
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10.3 Injectable treatments 
 
 
Injectable IFN beta drugs were the first disease modifying treatments for multiple sclerosis. 
Betaferon was approved for sale in Finland in 1995, Avonex in 1997, Rebif in 1998 and 
Extavia in 2008 (http://www.fimea.fi/laakehaut_ja_luettelot/laakehaku 12.7.2016). The 
mechanism of action is not completely clear, but these drugs are thought to shift the 
immune response from Th1 to Th2 reducing the occurrence of relapses approximately by 
30%, alleviating the symptoms and prolonging the time between the exacerbations (Palmer 
2013). Some patients develop neutralizing antibodies against IFN betas, which results in low 
IFN-induced MxA-levels (Palmer 2013). MxA-levels should be controlled 12 and 24 months 
after treatment onset and low levels should be controlled after 3-6 months (Palmer 2013). 
Antibody formation after 24 months is extremely rare (Palmer 2013). IFNs may cause 
headache, depression, liver enzyme elevation, thrombocytopenia and leukocytopenia 
(Palmer 2013). 
 
 
Glatiramer acetate (Copaxone®) received a trade license in Finland in 2004 
(http://www.fimea.fi/laakehaut_ja_luettelot/laakehaku 12.7.2016). It is a random polymer of 
four amino acids found in myelin basic protein (MBP) (Palmer 2013). The mechanism of 
action is thought to stem from tolerization to MBP and Th1-Th2 shift of immune response 
(Palmer 2013). Glatiramer acetate reduces the relapses by 32%, but has no effect on the 
relapse duration or severity (Palmer 2013). Glatiramer acetate can cause adverse 
cardiovascular effects, such as vasodilatation, tachycardia or difficulty in breathing (Palmer 
2013). Antibody formation is more infrequent in patients using glatiramer acetate than 
patients using interferons and thus laboratory surveillance is not required (Palmer 2013). 
Neither interferons nor glatiramer acetate seem to have effect on the long-term disability 
accumulation, but both reduce the amount of MRI lesions and delay conversion of CIS to 
RRMS (Palmer 2013).  
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10.4 Peroral treatments 
 
 
The first peroral treatment to receive a trade license in Finland was fingolimod (Gilenya®) 
(2011), the second was teriflumode (Aubagio®) (2013) and the third was dimethyfumarate 
(Tecfidera®) (2014) (http://www.fimea.fi/laakehaut_ja_luettelot/laakehaku 12.7.2016). 
Aubagio and Tecfidera belong to first-line treatments, but Gilenya is a second-line treatment 
(Multiple sclerosis: Current care guidelines 2015). 
 
 
Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator. Fingolimod mimicks S1P, 
binding to S1P receptor and causing their internalization. In the absence of S1P receptors 
lymphocytes fail to exit the lymph nodes reducing the amount of CNS penetrating 
lymphocytes. Fingolimod reduces the relapse rate significantly more than IFNs or glatiramer 
acetate (54%). It also reduces MRI lesions by 67%. Fingolimod has effect on atrioventricular 
conduction and may cause bradycardia and heart block. (Palmer 2013) 
 
 
Teriflunomide inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase (DHODH) 
reducing the pyrimidine neogenesis and thus also production of activated T cells. 
Teriflunomide reduces the relapse rate by 31%, its effect being comparable to IFNs and 
glatiramer acetate. It also reduces the amount of MRI lesions. Teriflunomide can cause for 
example influenza, paraesthesia, alopecia, liver enzyme elevation and gastrointestinal side 
effects. (Palmer 2013) 
 
 
Therapeutic effects of dimethyl fumarate are due to activation of Nrf2 pathway (nuclear 
factor like-2), which activates anti-oxidant pathways and is neuroprotective and anti-
inflammatory (Palmer 2013). It also shifts the immune response from Th2 to Th1 (Palmer 
2013). It reduces relapses by 44-53% and new gadolinium-enhancing lesion formation by 49-
89% (Palmer 2013). It can also inhibit disability progression (Palmer 2013). Dimethyl 
fumatare can cause flushing and gastrointestinal effects, lymphopenia, liver enzyme 
elevation and acute kidney injury (Elovaara et al. 2008).  
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10.5 Infusion treatments 
 
 
Mitoxnatrone (Novantrone®) has been on market in Finland since 1993, first as a treatment 
for cancer and since 1999 (28) for aggressive relapsing-remitting multiple sclerosis. 
Natalizumab (Tysabri®) was approved for sale in 2006 and alemtuzumab (Lemtrada®) in 
2013. Daclizumab (Zinbryta®) was approved for sale in 2016. 
(http://www.fimea.fi/laakehaut_ja_luettelot/laakehaku 12.7.2016) 
 
 
Both mitoxantrone and natalizumab reduce relapses by 66-67% and reduce MRI lesions by 
90%, but also retard disability progression in progressive forms of MS (Palmer 2013). 
Mitoxantrone is a humanized monoclonal antibody, which binds to DNA and RNA and exerts 
its cytotoxic effects on proliferative and nonproliferative cells (Palmer 2013). It inhibits the 
proliferation of T cells, B cells and macrophages, disrupts antigen presentation and reduces 
INF-gamma, TNFα and IL-2 secretion (Palmer 2013). Mitoxantrone increases the risk of 
infertility, leukaemia and cardiotoxicity (Palmer 2013). Mitoxantrone is administered as 
infusion every 3 months (Elovaara et al. 2008). Maximum cumulative dose for mitoxantrone 
is 120 mg, but usually 1-3 teatments are sufficient to alleviate the symptoms (Elovaara et al. 
2008, Multiple sclerosis: Current care guidelines 2015). 
 
 
Natalizumab binds to integrin α4β1 inhibiting interaction between it and vascular cell 
adhesion molecule-1 (VCAM-1) on endothelial cells, which inhibits the transmigration of 
mononuclear leukocytes into the CNS. Natalizumab thus also permits opportunistic 
pathogen ingress into the CNS. JC-virus can cause progressive multifocal 
leukoencephalopathy (PML), which may cause death or severe invalidity due to progressive 
white matter damage. Therefore berofe the first natalizumab-infusion the anti-JC-virus 
antibodies must be tested negative. Anti-JC virus antibodies, prior immunosuppression and 
increasing duration of natalizumab treatment increase the risk of PML. Natalizumab can also 
elevate liver enzymes and change blood cell levels, cause infusion reactions, such as 
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dizzyness, nausea, urticaria and rigidity and increase the risk of other infections, such as 
urinary tract infection or upper respiratory tract infections. Small amount of patients (6%) 
may develop neutralizing antibodies against natalizumab, which are tested 6 months after 
treatment onset. (Palmer 2013) 
 
 
Alemtuzumab is a humanized monoclonal antibody for CD52, a surface glycoprotein of T 
cells, B cells, monocytes and macrophages. Binding causes complement and antibody-
dependent cytotoxicity resulting in depletion of CD52 expressing cells. B cells recover 
rapidly, but CD4+ T cells take years to recover. Alemtuzumab elevates the levels of 
regulatory T cells and decreases the levels of memory T and B cells. Alemtuzumab decreases 
relapses by 49-55% and also the MRI findings are reduced and the disability accumulation is 
delayed. Alemtuzumab may increase the risk of developing other autoimmune diseases. 
(Palmer 2013) 
 
 
Daclizumab is monoclonal antibody for CD25, IL-2 receptor of the lymphocytes. Thus 
daclizumab prevents IL-2 dependent activation of lymphocytes. The phase II studies have so 
far shown 54-80,7% reduction in relapse rates and 70-78% reduction in MRI lesions in 
patients using different doses and formulations of daclizumab. Daclizumab can cause upper 
respiratory tract infections and pharyngitis, liver enzyme elevation and cutaneous effects, 
such as erythema and induration. (Palavra 2015) 
 
 
10.6 Emerging treatments 
 
 
10.6.1 Monoclonal antibodies 
 
 
New monoclonal antibodies (mAbs) are currently under investigation for treatment of 
multiple sclerosis. Ocrelizumab targets CD20 causing depletion of B cells (Palavra 2015). In 
the phase II studies ocrelizumab has reduced the relapse rates by 73-80% and amount of 
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new gadolinium-enhancing lesions on MRI scans by 89-99,8% (Palavra 2015). Ocrelizumab 
can cause infusion-related reactions, but no unexpected safety issues have emerged (Palavra 
2015). Phase III studies are currently ongoing for daclizumab and ocrelizumab and several 
mAbs are studied at the moment (Palavra 2015). mAbs are evidently effective in the 
treatment of RRMS, and at least alemtuzumab and natalizumab have been shown to reduce 
the disability accumulation and partially reverse disability (Palmer 2013).  
 
 
10.6.2 Stem cell therapies 
 
 
Stem cell therapies (SCTs) are currently under investigation for treatment of multiple 
sclerosis. Pluripotent stem cells have a capacity of cell replacement and neuroprotection. 
Adult stem cells (ASC) including hematopoietic stem cells (HSC), mesenchymal stem cells 
(MSC) and neural stem cells (NSC) as well as embryonic stem cells can be utilized, but the 
latter seem to be more prone to teratoma formation. MSCs and HSCs are usually derived 
from bone marrow and are capable of self-replication making the availability of HSCs and 
MSCs better than that of NSCs. Nevertheless only NSCs have the ability of remyelination and 
therefore additional study is needed especially regarding NSCs. (Meamar 2016) 
 
 
MSCs can be cultured in vitro and administered intrathecally. MSCs secrete several autocrine 
and paracrine factors that have neurotrophic and neuroprotective actions. Animal models 
have shown that MSC transplantation can suppress the CNS inflammation and reduce the 
clinical severity of the disease. (Meamar 2016) 
 
 
HSC transplantation aims at replacement of the immune system rather than 
neuroregeneration and thus re-establishment of tolerance to self-proteins. HSCs can be 
aspirated directly from the bone marrow or mobilized using intravenous chemotherapy or 
hematopoietic growth factors and collected by leukophoresis. (Meamar 2016). 
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NSCs are self-replicating multipotent progenitors of developing and adult CNS, which could 
provide a source of remyelinating cells. NSCs have neurotrophic, immunomodularory and 
neuroprotective properties. NSC transplantation has been shown to improve EDSS score and 
reduce the MRI lesions. The results of preclinical studies have been somewhat controversial, 
and no clinical trials regarding the NSC treatment are currently ongoing. (Meamar 2016). 
 
 
10.6.3 Laquinimod 
 
 
Laquinimod is an orally effective carboxamide derivative, taken once a day. Laquinimod has 
an ability to cross the bloob brain barrier and has multiple effects in and out of CNS. 
Laquinimod inhibits the entry of leukocytes into the CNS,  reduces the infiltration of CD4+ T 
cells, CD8+ T cells and macrophages, suppresses the Th17 proinflammatory responses, 
increases the amount of regulatory T cells and modulates the cytokine balance towards an 
anti-inflammatory milieu. Laquinimod has also effects on B-cell mediated activation of T cells 
and NF-κB pathways. Laquinimod has also neuroprotective properties resulting in decreased 
axonal damage, demyelination and oligodendrocyte apoptosis. (Thöne and Linker 2016) 
 
 
Laquinimod reduces modestly the amount of MRI lesions. Studies using low doses (0,3 
mg/day) found no significant effect on clinical exacerbations, EDSS or MSFC (Multiple 
Sclerosis Functional Composite). Doses of 0,6mg/day have been shown effective in reducing 
the annual relapse rates and risk of confirmed disability progression, but the information is 
somewhat conflicting. Lower rates of brain atrophy have also been observed.  
Studies on patients with relapsing-remitting and progressive multiple sclerosis and 
Huntington´s disease are currently ongoing. Laquinimod may answer to the unmet need of 
therapies for progressive disease forms. (Thöne and Linker 2016) 
 
 
10.7 Treatment goals  
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The treatment goals in MS have been amelioration of disease symptoms, to improve the 
quality of life and reduce the disability accumulation. Today potent and multiple disease 
modifying therapies have shifted the treatment goals towards the prevention by reducing 
the disease activity. In clinical trials first goals were reduction of annual relpse rate and 
attenuation of disease progression, however due to weak correlation with disease activity, 
MRI correlates were soon introduced as outcomes. New T2 lesions or gadolinium enhancing 
lesions were followed by new surrogates such as brain atrophy.  (Bevan et al. 2014, Fred 
2005, Whitaker et al. 1995) 
 
 
The term ‘no evidence of disease activity’ (NEDA) is a composite outcome measure for 
features such as no new or enhancing T2-weighed lesions, no new Gd enhancing lesions, no 
relapses and no confirmed worsening of Expanded Disability Status Scale scores. Brain 
volume loss have stronger correlation with disability and it has been suggested that they 
should be incorporated into NEDA. Unfortunately to date no therapy for MS has achieved a 
NEDA of geater than 50% and it appears that there will always be MS patients who worsen 
over time.  (Bevan et al. 2014) 
 
 
Aggressive MS requires therapy that eliminates disease-causing cells and therefore the first-
line and most second-line treatments are often ineffective (Rush et al. 2015). If the disease 
follows an aggressive course from the onset, according to the Finnish Current Care 
Guidelines second or third line treatments, alemtuzumab, natalizumab or fingolimod should 
be used (Multiple sclerosis: Current care guidelines 2015). Mitoxantrone can be used if the 
disease is resistant to these therapies (Multiple sclerosis: Current care guidelines 2015). 
Nevertheless only alemtuzumab and mitoxantrone deplete the disease-causing cells (Rush et 
al. 2015). These drugs can cause severe adverse effects, but the risks and benefits should be 
weighed individually (Rush et al. 2015). When other therapies have failed, stem cell 
transplantation might be appropriate (Rush et al. 2015). There are other drugs, such as 
cladribine, cyclophosphamide and rituximab, that deplete disease-causing cells, but those 
are not currently used in the management of aggressive MS (Rush et al. 2015). 
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10.8 Window of treatment opportunity 
 
 
It is postulated that factors early in the disease predict the later outcome and thus it is 
crucial to identify patients with aggressive disease early. The period of most intense 
inflammation occurring from the onset symptoms to probably some time before the 
conversion to secondary progression is the best opportunity for treatment with current 
DMTs. In aggressive MS this window of treatment opportunity is brief and can close 
suddenly due to rapid progression of the disease. The goal of treatment is to decelerate the 
speed of disability accrual and thus prevent the accumulation of permanent disability. Apart 
from clinically aggressive RRMS, for which induction treatment should certainly be regarded 
as the first line of treatment, there is a lack of biomarkers to guide early and safe choices 
between strategies at an individual level. (Edan and Le Page 2013)  
 
 
Classification of aggressive multiple sclerosis could be used in identification of patients who 
would need more aggressive treatments, as once a clinical threshold of irreversible disability 
is reached, the progression of disability is amnesic of the prior activity and clinical history of 
the disease (Leray et al. 2010). Beyond EDSS 6 the risk-benefit ratio might be unfavourable 
(Rush et al. 2015). 
 
 
In a study of Kaunzer et al. (2016) 43 patients with aggressive onset multiple sclerosis 
(AOMS) were selected for follow-up. Only two patients out of 35 who received first-line 
medications had NEDA and 22 of them were switched on more aggressive treatments. 7 out 
of 8 patients who were initially started on aggressive therapies had NEDA. This indicates the 
need of early optimal treatment for patients suffering from aggressive MS. If the patients 
showed no change in baseline neurological exam, no relapses and no new or enlarging T2 
lesions or gadolinium-enhancing lesions on the MRI scan, they were classified as NEDA. 
(Kaunzer et al. 2016) 
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11 MATERIALS AND METHODS  
 
 
 
11.1 Case ascertainment 
 
 
Patients with multiple sclerosis in the health care district of Tampere University Hospital 
district at Pirkanmaa were recruited in the study from the hospital administrative data 
registry. The study cohort was selected among 478 cases who had received multiple sclerosis 
(ICD-10 G35), morbus demyelinans (ICD-10 G37) or retrobulbar or optic neuritis (ICD-10 H46) 
diagnosis between January 2010 and December 2014. Most of them were initially diagnosed 
before 1 January 2010 or outside the Pirkanmaa district and some of them did not 
eventually have multiple sclerosis. Therefore 276 cases were excluded and 202 cases that 
filled the McDonald diagnostic criteria for definite diagnosis were included in the study. 
Disease course was classified into RRMS, PPMS and CIS based on criteria by Lublin and 
Reingold (2014). In Finland, all MS patients are diagnosed by a neurologist according to the 
McDonald diagnostic criteria (2010). Kurzke Extended Disability Status Scale (EDSS) is used in 
determination of disability (Kantarchi and Weinschenker 2005).  
 
 
Patient records of the confirmed MS patients were carefully scrutinized. We collected results 
on diagnostic MRI, CSF and EP studies. CSF and MRI are routine studies in diagnostics of MS 
in Finland. Information was collected on the date and quality of the first symptom, the 
number of possible relapses prior to diagnosis, time lag between initial symptoms and 
diagnosis, disease modifying therapy, comorbidities, pregnancies and smoking. We recorded 
available MRI dates and findings, including inflammatory activity, new lesion formation and 
atrophy for the first as well as for the following MRIs. Expanded Disability Status Score 
(EDSS) was collected at any medication start timepoint and at the end of follow up in 15 
June 2016. In case of loss of follow-up, the last EDDS value closes to the follow-up date was 
used as the final EDSS value. A detailed description on three cases with natalizumab 
treatment in active MS at onset is included. 
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11.2 Method 
 
 
We calculated the crude and age-adjusted incidences for all cases as well as by gender with 
95% confidence intervals per 105 person years from 1 January 2010 to 31 December 2014. 
Kaplan Meyer (KM) analysis was employed to study survival and significance was given using 
log lank test. Survival was assessed from disease onset year and year of birth up to the end 
of follow up in 15 June 2016. In the survival analyses EDSS 2.5 was used as an endpoint. The 
hazard ratios (HR) with 95% confidence interval (95% CI) in Cox’s univariable and 
multivariable regression analyses are given.  
 
 
Categorization for first symptoms resulted in five groups: Visual, sensory, motor, brainstem 
or multiple/other. The study population was categorized by smoking status into active, past 
and non-smokers. Distribution of cases by medication, EDSS at medication start in ten-year 
age groups, final EDSS and EDSS change during the five-year follow-up were studied.  
 
 
 
12 Results 
 
 
 
12.1 Demographics of the study population 
 
 
From 1 January 2010 to 31 December 2014 altogether 202 MS cases fulfilled the inclusion 
criteria of definite MS by the McDonald diagnostic criteria (2010). 18 cases (8.9%) were lost 
to follow up and 11 (5.4%) due to migration. None of the patients died during the follow-up 
period and the follow-up information up to 15 June 2016 was complete. The population of 
Pirkanmaa was 524 447 in the end of 2014. The age-structure remained the same during the 
5-year follow-up period (Figure 1). 
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Characteristics of the patients are shown in Table 1. 72.8% (n=147) of cases were female and 
27.2% (n=55) were male, the female/male-ratio being 2.7. 92.6% (n=188) of all MS cases 
were RRMS and 7.4% (n=14) were PPMS. Most frequent onset symptoms originated from 
visual tract (33.7%, n=68), sensory tracts (32.7%, n=66), and brainstem (16.3%, n=33). 
Median age at onset symptom was 31 years and at diagnosis 35 years. Most RRMS patients 
had had one (34.7%) or two (49.4%) attacks before diagnosis. The median diagnostic delay 
was 1.0 years. 
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12.2 Case ascertainment and assessment of MRI 
 
 
McDonald 2010 criteria were applied. MRI was performed at least once in all cases and CSF 
studies in 96,0% of cases. EP studies were used in only 5.9% of cases and 58.3% of EP studies 
were positive. The IgG-index was abnormal in 87.7% of RRMS cases and 84.6% of PPMS 
cases. The first MRI was indicative of MS in 93.0% of all cases. Activity in first MRI was 
recorded in 42.0% of RRMS cases and in 7.1% of PPMS cases. Brain atrophy was observed in 
the first or follow-up MRIs in 46.2% of PPMS cases and in 13.3% of RRMS cases.  
 
Table 1: Characteristics of cases.
N   %
Number of cases
Total 202
Female 147 72.8%
Male 55 27.2%
F/M-ratio 2.7
Disease course
CIS 12 5.9%
MS 190 94.1%
RRMS 176 92.6%
PPMS 14 7.4%
Age at onset
Median 31
Mean 32
Age at diagnosis
Median 35
Mean 36
Diagnostic delay, years
Median 1.0
Mean 4.1
SD 5.9
Visual tract 68 33.7%
Sensory 66 32.7%
Brainstem 33 16.3%
Motor 19 9.4%
Multiple 14 6.9%
Other 2 1.0%
Comorbidities
Obesity 32 15.8%
Metabolic 29 14.4%
First symptom by anatomic level
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12.3 Use of disease modifying treatment 
 
 
During the follow-up 73.9% (130/176) of RRMS patients started medication with a first line 
DMT treatment: Avonex® in 22 cases, Betaferon® or Extavia® in 20, Copaxone in 13, Rebif® 
(22 μg or 44 μg) in 69, Aubagio® in 4 and Tecfidera® in 2. In 53.0% of cases the choice of 
primary treatment was Rebif®. In four cases treatment was started with natalizumab and in 
four cases treatment in randomized controlled trial (RCT) remained unknown. 38 RRMS 
patients did not use any disease modifying treatment.  
 
 
12.4 Comorbidities and smoking  
 
 
Active smoking was observed in 24.3% (n=49) of patients during the follow-up period, 14.4% 
(n=29) of them were past smokers and 43.1% (n=87) did not smoke. In 16.8% (n=37) of cases 
smoking status was unknown.  
 
 
Most (n=113, 55.9%) patients were not reported to have any comorbidities. Most commonly 
patients were obese (n=32, 15.8%) or had one or more metabolic comorbidities (hypertonia, 
hypercholesterolemia or diabetes mellitus type II) (n=29, 14.4%). Results are shown in Table 
1. 
 
 
12.5 Incidence  
 
 
From January 1 2010 to December 31 2014 the crude incidence was 7.8 (95% CI: 6.7-8.9) for 
all cases, 4.3 (95% CI: 3.2-5.4) for men and 11.2 (95% CI: 9.4-13.0) for women. The total age-
adjusted incidence was 10.3 (CI 95%: 8.8-11.7), 6.5 (95% CI: 4.8-8.2) for men and 15.1 (95% 
CI: 12.7-17.5) for women.  
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Incidence was highest in patients with RRMS in the age group of 30-39 years (19.6, 95% CI: 
14.9-24.3) and in PPMS in the age group of 40-49 years (2.1, 95% CI 0.6-3.7). The total 
incidence for both disease courses and genders was highest in the age group of 30-39 years 
(21.1, CI 95%: 16.2-26.0). Age specific incidences were higher for women in the age-group of 
10-49 years and for men in the age-group of 50-69 years. The highest F/M-ratio was 
observed in the 10-19 year-age group, in which 9 female and no male patients were 
observed. The F/M-ratio was 1.0 in the age group of 50-69 years. 
 
 
12.6 Disability progression in the incidence cohort  
 
 
Factors associated with a risk of reaching the endpoint of EDSS 2.5 by the end of the follow-
up period were analyzed by KM and Cox regression models for the incidence cohort of 202 
MS patients from diagnosis. 
 
 
The mean follow-up time from diagnosis to the end of the follow-up period in 15 June 2016 
in the incidence cohort was 5.5 years (5.3-5.7), median was 6.4 years (5.8-6.9). Mean follow-
up time in RRMS was 5.7 years (5.4-5.9), median was 6.4 years (5.8-6.9). Mean follow-up 
time in PPMS was 3.6 years (2.8-4.5) and median was 3.8 years (0.95-6.7).  
 
 
In KM analysis the risk of progression from timepoint of diagnosis up to the end point of 
EDSS 2.5 at the end of follow-up for PPMS patients was significantly faster than that for 
patient with RRMS patients (log rank p=0.00). (Figure 2). 
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Factors associated with a risk of reaching the endpoint of EDSS 2.5 by the end of the follow-
up period in the univariable and multivariable Cox models are shown with HRs and 95% 
confidence intervals in Table 2. PPMS (p=0.040), longer diagnostic delay (p=0.000) and 
higher age at first symptoms (p=0.005) in both univariable and multivariable model showed 
a statistically significant risk. Same was true for visual (p=0.008), sensory (p=0.037), motor 
(p=0.000) and multiple (p=0.011) first symptoms. In adjusted model no association was 
found with gender, level of IgG index at diagnosis, first symptoms of brainstem level or 
number of comorbidities.  
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Time to end point of EDSS 2.5 at the end of follow-up was shorter among active smokers 
than that of non-smokers or past smokers in the KM analysis, but the difference was not 
statistically significant (log rank p=0.121) (Figure 3). 
 
 
Table 2: Cox model. Risk of reaching EDSS 2.5 by the end of follow up in the incidence cohort (n=202). 
HR 95% CI P HR 95% CI P
Disease course
RRMS 1.0 1.0
PPMS 7.4 3.8-14.2 0.000 2.7 1.0-6.8 0.040
First symptom
Visual tract 1.0 0.000 1.0 0.008
Sensory 2.5 1.0-6.1 0.050 3.2 1.1-9.3 0.037
Motor 9.6 3.6-25.6 0.000 10.1 2.8-36 0.000
Brainstem 2.4 0.86-6.6 0.094 2.4 0.63-9.1 0.197
Multiple 3.5 0.89-13.5 0.072 6.8 1.6-23 0.011
Other 4.8 0.58-39.1 0.146 2.5 0.39-2.1 0.425
Gender
Female 1.0 1.0
Male 1.6 0.85-2.9 0.147 0.9 0.39-2.1 0.796
Smoking status
No smoking 1.0 0.165 1.0 0.322
Active smoker 1.8 0.85-3.7 0.125 2.3 0.92-5.7 0.075
Past smoker 0.54 0.16-1.9 0.328 1.0 0.25-3.9 0.992
Smokig status unknown 1.6 0.72-3.4 0.251 1.3 0.55-3.1 0.548
Diagnostic delay 1.1 1.0-1.1 0.001 1.1 1.1-1.2 0.000
Age at initial symptoms 1.1 1.1-1.1 0.000 1.1 1.0-1.1 0.005
IgG index 0.98 0.56-1.7 0.941 1.2 0.66-2.1 0.569
Number of comorbidities 1.0 0.85-1.2 0.777 1.0 0.82-1.3 0.854
UNIVARIABLE            MULTIVARIABLE
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12.7 Disability progression in RRMS group  
 
 
In the separate Cox analysis for the RRMS group (n=176) is shown in Table 3. Active smoking 
(p=0.047), longer diagnostic delay (p=0.000) and higher age at first symptoms (p=0.003) 
were statistically significantly associated with reaching the endpoint in both univariable and 
multivariable models. Same was true for motor (p=0.005) and multiple first symptoms 
(p=0.013). 
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In this analysis, we excluded the four aggressive cases who started treatment with 
natalizumab and cases with unknown or study treatment.   
Total of 130 cases started with a first line DMT and in 38 cases no treatment was started. 
The KM survival from timepoint of definite MS diagnosis to EDSS 2.5 at the end of follow up 
was beneficial among patients who started DMT (log rank p=0.006) (Figure 4). Mean follow-
up time in DMT group was 5.9 years (5.6-6.1) and in no treatment group 5.1 years (4.5-5.7). 
 
 
Table 3: Cox model. Risk of reaching EDSS 2.5 by the end of follow up in the RRMS group (n=176).
HR 95% CI P HR 95% CI P
First symptom
Visual tract 1.0 0.088 1.0 0.073
Sensory 1.8 0.68-4.7 0.241 3.0 0.95-9.3 0.061
Motor 5.3 1.6-16.8 0.005 7.4 1.8-29.7 0.005
Brainstem 1.7 0.53-5.4 0.368 2.7 0.68-10.6 0.160
Multiple 3.5 0.89-13.5 0.074 6.6 1.5-29.0 0.013
Other 4.8 0.58-39.2 0.146 2.4 0.24-23.1 0.461
Gender
Female 1.0 1.0
Male 1.0 0.47-2.4 0.908 0.77 0.29-2.1 0.596
Smoking status
No smoking 1.0 0.467 1.0 0.219
Active smoker 1.6 0.63-3.9 0.342 3.3 1.0-10.6 0.047
Past smoker 0.7 0.20-2.6 0.609 1.1 0.28-4.6 0.860
Smokig status unknown 1.7 0.68-4.2 0.265 1.5 0.52-4.4 0.444
Diagnostic delay 1.1 1.0-1.1 0.000 1.1 1.1-1.2 0.000
Age at initial symptoms 1.1 1.0-1.1 0.004 1.1 1.0-1.1 0.003
IgG index 0.95 0.48-1.9 0.874 1.4 0.64-3.1 0.402
Number of comorbidities 1.1 0.87-1.3 0.543 1.0 0.79-1.3 0.869
UNIVARIABLE                  MULTIVARIABLE
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In Cox model, the non-DMT users had a significant risk of reaching the endpoint of EDSS 2.5 
by the end of follow-up in the univariable model. No risk was observed when other 
modulators were included in the model. The statistically significant modulators were 
diagnostic delay and age at onset. Results are shown in Table 4.  
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The effects of disease activity, common comorbidities and smoking in disability progression 
were analyzed.    
 
 
In Cox regression analysis of RRMS group active smokers who had comorbidities (depression 
and/or diabetes) had a statistically significant risk to reach the endpoint of EDSS 2.5 (p=0.02) 
in univariable analysis. Active smoking doubled the risk in multivariable model when 
adjusted for other modifiers presented in Table 5. (HR 2.6, CI 95% 1.2-5.7, p=0.02). DMT use, 
comorbidities and gender showed no significant risk. 
 
 
Table 4: Cox model. Risk of conversion to EDSS 2.5 or more up to the follow-up among cases
who started treatment with first line DMT (n=130). 
UNIVARIABLE MODEL MULTIVARIABLE MODEL
N HR 95% CI P HR 95% CI P
DMT use
DMT 130 1.0
No DMT 38 2.8 1.3-5.9 0.11 1.9 0.47-3.2 0.74
First symptom
Visual tract 57 1.0 0.133 0.17
Sensory 54 1.0 0.38-3.2 0.86 1.6 0.52-5.3 0.46
Motor 13 4.1 1.3-13.1 0.17 5.1 1.3-19.3 0.018
Brainstem 28 1.6 0.49-5.0 0.44 1.8 0.48-6.4 0.39
Multiple 14 2.8 0.72-11.1 0.14 4.0 0.91-17.3 0.065
Other 2 3.7 0.45-30.6 0.22 2.2 0.25-19.8 0.48
Diagnostic delay (years) 168 1.1 1.0-1.1 0.000 1.2 1.1-1.2 0.001
Age at initial symptoms (years) 168 1.1 1.0-1.1 0.000 1.1 1.0-1.1 0.001
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13 DISCUSSION 
 
 
 
We studied the 5-year incidence and effects of DMT and several prognostic factors in MS 
survival up to 15 June 2016 in an incidence cohort diagnosed from 2010 to 2014 in the 
University Hospital of Tampere in western Finland.  
 
 
The population of the Pirkanmaa district is fairly large and genetically homogenous with the 
rest of the Finnish population. In Finland MS patients are diagnosed by neurologists. Thus 
the study cohort is expected to be representative of the Finnish MS patient population. We 
believe that we were able to discover all new cases in the follow up time since we selected 
all patients who had received multiple sclerosis, morbus demyelinans or retrobulbar or optic 
neuritis diagnosis between 1 January 2010 and 31 December 2014 and included only the 
true multiple sclerosis patients who were diagnosed in the follow up period. Some of the 
benign cases that have initiated in the time span may have remained unnoticed due to more 
inconspicuous symptoms.  
 
Table 5: Follow-up of the DMT group (n=130) from medication start to need for change to 
more efficient immunomodulatory treatment.
HR 95% CI P HR 95% CI P
Age at DMT start 0.97 0.93-1.0 0.072 0.97 0.93-1.0 0.093
Time from diagnosis to first 
DMT
1.0 1.0-1.0 0.123 1.0 1.0-1.0 0.325
First symptom
Visual tract 1.0 0.144 1.0 0.249
Sensory 2.2 0.88-5.3 0.092 2.3 0.92-5.6 0.077
Motor 2.6 0.75-8.8 0.131 3.0 0.86-11 0.085
Brainstem 3.8 1.4-11 0.010 3.0 1.0-8.7 0.047
Multiple or other 1.8 0.22-15 0.587 1.5 0.2-13 0.705
Gender 1.1 0.50-2.4 0.802 1.1 0.49-2.5 0.796
UNIVARIABLE MODEL MULTIVARIABLE MODEL
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First of all we observed a rapid increase in incidence in a genetically stable population during 
a 5-year follow-up. The age-adjusted incidence has increased considerably from 6.7 per 105 
in 1981-2010 to 10.3 per 105 in 2010-2014 (4). Such a rapid increase points at environmental 
effects and the increased hunt for MS in the presence of several immunomodulating 
treatments available during this period. From 2010 McDonald criteria have allowed a rapid 
MS diagnosis, shown also in this cohort. The mean diagnostic delay has decreased from 2.0 
years before 2010 to 1.0 years in 2010-2014. This slight decrease indicates the effect of 2010 
revised diagnostic criteria based mainly on magnetic resonance imaging (MRI) findings.  
 
 
The age adjusted incidence was higher among women compared to men compared to the 
previous Finnish study (Sumelahti et al. 2014). Consistent with the earlier findings the F/M-
ratio was highest in the younger age groups and the ratios were equal between genders in 
the older age groups (50-69 years) (Sumelahti et al. 2014). The youngest patient was 13 
years old and the oldest was 68 years old at the time of diagnosis indicating a broad age 
spectrum in the MS patients. The demographics of the study population were consistent 
with earlier studies considering the distribution of PPMS and RRMS cases, female/male ratio 
and distribution of onset symptoms (Sumelahti et al. 2014). 
 
 
In the previous Finnish study 1981-2010, 89% of patients presented with RRMS and the rest 
with PPMS. In the 1964-1993 study 21% of all confirmed MS patients had PPMS. In our study 
92.6% were RRMS and 7.4% PPMS indicating a decreasing trend of PPMS and increasing 
trend of RRMS. In our study RRMS was most common in the age group of 30-39 and PPMS in 
the age group of 40-49. In concordance with other studies (Gholipour et al. 2011, Kantarchi 
and Weinshenker 2005, Levic et al. 1999) the risk of progression from diagnosis up to the 
end point of EDSS 2.5 for PPMS patients was significantly higher than that for RRMS patients.  
 
 
Several modifiers in disease prognosis were assessed. Consistent with earlier studies 
multifocal and motor first symptoms, but in our multivariable Cox regression analysis also 
visual and sensory symptoms were associated with a worse short-term prognosis when 
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analyzing the incidence cohort (Gholipour et al. 2011). This is somewhat contrary to previous 
findings that have shown visual and sensory symptoms to be associated with a better 
prognosis and multifocal, motor, cerebellar and sphincter symptoms with a worse prognosis 
(Gholipour et al. 2011). However, in the multivariable Cox analysis for RRMS group the visual 
and sensory first symptoms lost their significance and only motor and multifocal symptoms 
were associated with a worse prognosis. This could be worth considering at the time of 
diagnosis of patients with multiple first symptoms or motor first symptoms. The gender was 
not found to be associated with a higher risk of reaching the endpoint. Higher IgG index or 
activity in first MRI were not found to be associated with a higher risk of reaching the EDSS 
2.5 but are still important in differential diagnostics of multiple sclerosis. 
 
 
The risk of progression was significantly higher if the diagnostic delay was longer or patient 
was older at the time of diagnosis pointing at beneficial risk among cases with a short 
diagnostic delay and young age at the time of diagnosis. The risk of progression to EDSS 2.5 
was highest if the diagnostic delay was over ten years. This indicates that even in cases with 
inactive disease during the first ten years disease progresses significantly without any 
disease modifying treatment, the progression being faster in the later years of the disease. 
Benign course of MS is a controversial topic (Correale et al. 2012a, b), and eventual 
progression observed among cases with a slow progression at disease start favors for DMT 
start also in this activity subgroup.  
 
 
In KM analysis whether the RRMS patient who had started a first line DMT reached the 
endpoint of EDSS 2.5, we found that patients who did not use any disease modifying 
treatment had significantly higher risk of progression to EDSS 2.5 than those who used 
disease modifying treatment. Since the faster progression in the group without medication is 
evident in such a short follow up period it would be important to prevent this disability 
accumulation by starting DMT early enough. The results were studied by logistic regression 
including several modifiers into model. In this analysis, independent survival benefit was 
significant among cases with a short diagnostic delay and younger age at onset, while DMT 
use showed no independent effect. Results points at importance of early diagnosis and 
related rapid start of DMT use. 
 
42
 
 
In our study disease progression among active smokers was more rapid than among 
nonsmokers in the incidence cohort, but the difference was not statistically significant. In 
RRMS group active smoking showed an independent risk for disease progression when 
several modifiers, including common comorbidities in this cohort were included. Smoking 
showed a higher risk than comorbid depression and diabetes and was the most significant 
predictor of adverse survival, even in the presence of active immunomodulatory treatment. 
According to this result is essential to advise patients with MS to cease smoking. Smoking is 
known to be an important risk factor of multiple sclerosis and it also accelerates the 
disability accrual (Hawkes 2007, Healy et al. 2009, Hedström et al. 2013, Hernan et al. 2005, 
Riise et al. 2003).  Comorbid conditions are known to decrease to quality of life in MS and 
may bring along life style related negative factors which should be considered in patient 
counseling and treatment planning. It would be important to study further the long-term 
effects of smoking since we were able to observe a significant survival disadvantage in such a 
short follow-up period indicating that smoking is a strong risk factor for faster disability 
accrual. 
 
 
The short follow-up period allowed us to study only a short-term prognosis to the endpoint 
of reached EDSS 2.5. Yet we were able to observe a strongly increasing incidence of MS in 
the district of Pirkanmaa and several factors indicating worse prognosis. This may indicate 
that factors seen in long term follow up (Eriksson et al. 2003, Kantarchi and Weinshenker 
2005, Runmarker and Andersen 1993) are observed also during the short-term studies, 
which makes follow-ups like ours meaningful today, considering the significant changes in 
the field on MS treatment. Strength of the study is the public healthcare which allows that 
all MS patients are diagnosed and treated in central or university hospitals. Patient records 
were carefully studied by the author and all the relevant information achievable was taken 
on account. However, retrospective research of the patient records may contain a reporting 
bias since patients tend to not report undesirable matters, such as smoking or the clinician 
may forget to ask or report it to the patient records. Information on depression and 
diagnosed diabetes may be considered reliable in this study, due to careful recording of 
concomitant medications observed in patient documents. 
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Aggressive disease course was observed in only four cases at MS onset. This was assessed by 
a need of second line treatment as a primary medication. These cases represent the effect of 
induction therapy for aggressive MS instructed in Finnish Current Care guide lines. Small 
number in this cohort which is less than 4-14 % reported in other studies and may be 
explained by the short follow up period (Menon et al. 2013). Recognition and active 
treatment of aggressive disease course is justified according to this notion. Early treatment 
start in general is supported by observation of a more benign prognosis among the DMT 
treated patients.  
 
 
 
14 CONCLUSION 
 
 
 
The ultimate goal of MS treatment is to preserve CNS functions. We found that disability 
progression in MS may be observed during the first five years after diagnosis and 
progression is significantly altered by primary progressive disease course, older age at onset, 
delayed diagnosis and active smoking. First line DMT use in RRMS group was related to a 
more beneficial survival assessed by time to reach EDSS 2.5. However, effects of rapid 
diagnosis and initial age showed an even stronger association to survival benefit in MS 
pointing at importance of early diagnosis and related start of efficient treatment. This study 
also points that treatment effects assessed by disability progression in majority of cases may 
need a longer follow-up time.  
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